251 related articles for article (PubMed ID: 16906036)
1. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation.
Taylor AL; Bowles KM; Callaghan CJ; Wimperis JZ; Grant JW; Marcus RE; Bradley JA
Transplantation; 2006 Aug; 82(3):375-81. PubMed ID: 16906036
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
5. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
6. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
[TBL] [Abstract][Full Text] [Related]
7. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.
Marino D; Burra P; Boccagni P; Calabrese F; Canova F; Trentin C; Boso C; Soldà C; Angeli P; Aversa SM
Anticancer Res; 2010 Jun; 30(6):2383-91. PubMed ID: 20651397
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment.
Aversa SM; Stragliotto S; Marino D; Calabrese F; Rigotti P; Marchini F; Gambino A; Feltrin G; Boso C; Canova F; Soldà C; Mazzarotto R; Burra P
Acta Haematol; 2008; 120(1):36-46. PubMed ID: 18797163
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
Birkeland SA; Hamilton-Dutoit S; Bendtzen K
Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802
[TBL] [Abstract][Full Text] [Related]
12. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
[TBL] [Abstract][Full Text] [Related]
14. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
[TBL] [Abstract][Full Text] [Related]
15. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
Lee JJ; Lam MS; Rosenberg A
Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant lymphoproliferative disorders in transplant recipients.
Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant lymphoproliferative disorder: morphological picture and diagnostic difficulties.
Ziarkiewicz-Wróblewska B; Górnicka B; Suleiman W; Ołdakowska-Jedynak U; Wróblewski T; Bogdańska M; Ziółkowski J; Nowacka-Cieciura E; Foroncewicz B; Pileri SA; Durlik M; Paczek L; Krawczyk M; Wasiutyński A
Transplant Proc; 2006; 38(1):168-72. PubMed ID: 16504694
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience.
Buell JF; Gross TG; Hanaway MJ; Trofe J; Muthiak C; First MR; Alloway RR; Woodle ES
Transplant Proc; 2005 Mar; 37(2):956-7. PubMed ID: 15848588
[TBL] [Abstract][Full Text] [Related]
20. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Trappe RU; Choquet S; Reinke P; Dreyling M; Mergenthaler HG; Jäger U; Kebelmann-Betzing C; Jonas S; Lehmkuhl H; Anagnostopoulos I; Leblond V; Hetzer R; Dörken B; Riess H; Oertel S
Transplantation; 2007 Dec; 84(12):1708-12. PubMed ID: 18165786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
